Clinical testing of amipaque for cerebral angiography

Amundsen, Per; Dugstad, G.; Slettebö, M.

doi:10.1007/bf00334121

Cited by 25 publications

(1 citation statement)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Intravascular radiocontrast agents have been widely used in various diagnostic procedures. 10,11,20,26,31,41,45,69,88,95,96,129,138,169,181,188 Numerous re ports on varying degrees of adverse reactions during and after their use have been published. [2][3][4]19,21,24,25,40,43,44,46,66 These reactions can be classified as minor, intermediate, and severe and are listed in Figure 23.…”

Section: Discussionmentioning

confidence: 99%

Molecular Markers of Contrast Media-Induced Adverse Reactions

Fareed¹,

Moncada²,

Messmore³

et al. 1984

Semin Thromb Hemost

View full text Add to dashboard Cite

Currently used routine laboratory screening methods are not reliable in the prediction of contrast media-related adverse reactions. Cost-effective laboratory methods for various molecular markers of pathophysiologic activation have now become available. In vitro activation tests in high-risk patients may prove to be useful in the prediction of contrast-induced activation of various adverse reactions. If prior clinical evaluation of a patient suggests an ongoing pathologic process, profiling of the following molecular markers may prove to be useful and helpful in avoiding contrast-induced adverse reactions: Fibrinopeptide A, platelet factor 4, thromboxane B2, 5-HETE, physiologic inhibitors of proteases, B beta 15-42 related peptides, bradykinin/kininogen, and anaphylactozins. In patients suspected of reacting to contrast agents, a small dose of 1 to 5 ml can be injected as a bolus and molecular marker profiling on blood drawn after the infusion may prove to be useful screening tests. Additional clinical studies are needed to prove this. However, this screening test should be performed with extreme caution, since some of the patients are known to react to as little as 1 ml dose. The safety of newly developed nonionic contrast agents can be readily assessed by profiling various molecular markers of adverse reactions, which provide a more reliable and quantitative assessment of contrast-induced adverse reactions. Based on molecular marker profiling, various prophylactic agents can be given to high-risk patients to avoid contrast-induced adverse reactions.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Markers of Contrast Media-Induced Adverse Reactions

Fareed¹,

Moncada²,

Messmore³

et al. 1984

Semin Thromb Hemost

View full text Add to dashboard Cite

show abstract

Iohexol compared to meglumine-Ca-metrizoate in common carotid angiography

1983

View full text Add to dashboard Cite

A randomized double blind cross-over study with iohexol (Omnipaque) and meglumine-Ca-metrizoate (Isopaque cerebral) was performed to answer questions concerning subjective side effects and tolerability that arose from a double blind parallel study with the same two media. The cross-over study design, with injection of the contrast media under identical conditions in the same artery, seems to be the most practical method of comparison of two well tolerated media. Iohexol showed significantly less side effects than meglumine-Ca-metrizoate. The routine premedication with atropine was neglected in this study to evaluate effects on heart rate due, for example, to the toxicity of the media. Small tachycardial and bradycardial reactions were equally divided between the media. However, a short asystolic period following the injection of meglumine-Ca-metrizoate in two different patients may indicate a higher toxicity of this medium.

show abstract

ECG changes during cerebral angiography

et al. 1984

View full text Add to dashboard Cite

We have analyzed HR changes greater than 20% among 334 patients and 942 cerebral angiographies. A tachycardial effect was seen in 14.9% of patients, while a bradycardial effect was seen in 7.1% including two patients having cardiac standstill (0.5%). These two patients were examined without atropine premedication after subarachnoid hemorrhage. Patients under 19 years of age, unpremedicated with atropine sulfate and suffering from subarachnoid hemorrhage secondary to ruptured aneurysm or arteriovenous malformation showed a significantly high incidence of bradycardia. On the other hand, patients with the neoplastic disease and having an initial sinus bradycardia showed a significantly high incidence of a tachycardial effect.

show abstract

Clinical testing of amipaque for cerebral angiography

Cited by 25 publications

References 15 publications

Molecular Markers of Contrast Media-Induced Adverse Reactions

Molecular Markers of Contrast Media-Induced Adverse Reactions

Iohexol compared to meglumine-Ca-metrizoate in common carotid angiography

ECG changes during cerebral angiography

Contact Info

Product

Resources

About